Send to

Choose Destination
Drug Saf. 2019 Feb;42(2):199-209. doi: 10.1007/s40264-018-0771-y.

Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.

Author information

Division of Pulmonary Oncology, Azienda Ospedaliera Dei Colli Monaldi, Naples, Italy.
"Luigi Vanvitelli" University, Caserta, Italy.
Division of Medical Oncology, "S.G. Moscati" Hospital, Contrada Amoretta, 83100, Avellino, Italy.


The chimeric protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, resulting from the rearrangement of the homonym genes, is one of the currently targetable oncogenic drivers in anaplastic lymphoma kinase-positive non-small-cell lung cancer. In fact, four first- and second-generation anaplastic lymphoma kinase tyrosine kinase inhibitors, crizotinib (PF-02341066), ceritinib (LDK378), alectinib (CH5424802), and brigatinib (AP26113), are presently approved for clinical practice; however, these agents are not devoid of complications and thus should be administered meaningfully. Furthermore, third-generation inhibitors are currently under development to overcome acquired resistance mechanisms inevitably resulting from treatment with first- and second-generation tyrosine kinase inhibitors. Therefore, this article aims to provide a comprehensive state-of-the-art review about the pharmacodynamics, pharmacokinetics, safety, and tolerability profiles of currently available and promising under-development anaplastic lymphoma kinase tyrosine kinase inhibitors.


Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center